Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
Ibrutinib dose modifications in the management of CLL
Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) in 2014. Ibrutinib is often used to treat patients who are younger than the patients originally ...